Trending...
- Spokane: Flags Lowered for Peace Officers Memorial Day
- The Simplest Small Business You're Probably Not Thinking About
- All About Technology Celebrates 25 Years of Bridging Detroit's Digital Divide
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. ("Daiichi Sankyo") relating to the parties' 2008 collaboration agreement for the use of Seagen's antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract.
"While we are disappointed with the arbitration decision, it was important for us to pursue this legal action," said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical Officer, Seagen. "This does not impact our existing business. Looking forward, we are well-positioned to drive continued innovation and growth with four commercial products and a deep and diverse pipeline of promising programs. Seagen remains focused on developing innovative medicines that make a meaningful difference in the lives of cancer patients."
More on Washingtoner
About Seagen
Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Forward Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen's continued innovation and growth, as well as its pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the risk that the company's financial results may not be as expected and the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by the company is contained under the caption "Risk Factors" included in Seagen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.
More on Washingtoner
Contacts
For Media
David Caouette
(310) 430-3476
dcaouette@seagen.com
For Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com
"While we are disappointed with the arbitration decision, it was important for us to pursue this legal action," said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical Officer, Seagen. "This does not impact our existing business. Looking forward, we are well-positioned to drive continued innovation and growth with four commercial products and a deep and diverse pipeline of promising programs. Seagen remains focused on developing innovative medicines that make a meaningful difference in the lives of cancer patients."
More on Washingtoner
- Spokane: Coffee With Council District 2 Council Members
- Tacoma: Implementation of Transportation Impact Fees to Begin on June 1
- City of Tacoma Highlights Performance Milestones, Efficiency of Alternative Response Programs
- Lick Introduces Pineapple Flavored Massage Oil — A Tropical Date Night Favorite Available on Amazon
- FutureLot Powers ADU Wizard for Massachusetts Clean Energy Center's Statewide ADU Resource Center
About Seagen
Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Forward Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen's continued innovation and growth, as well as its pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the risk that the company's financial results may not be as expected and the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by the company is contained under the caption "Risk Factors" included in Seagen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.
More on Washingtoner
- ICT Innovations Releases ICTPBX Community Edition as Open Source Under Mozilla Public License 2.0
- Spokane: City Closures Planned for Memorial Day
- Spokane: Child Injured in Basement Fire Reminds About Youth Fire Setting
- Maryland Personal Injury Firm Earns National Recognition in 2026 ELA Awards
- Children's Author Releases Second Inspiring Career Book
Contacts
For Media
David Caouette
(310) 430-3476
dcaouette@seagen.com
For Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com
0 Comments
Latest on Washingtoner
- NewReputation's AI Sentiment Analysis Tool Reaches 2,500 Users as Businesses Demand Clearer Brand Intelligence
- CAPO Supply Announces Opening of Second Location in New Castle, Pennsylvania
- $224 Billion Growing Market in Life Settlements Presents Major Opportunity for New Policy Acquisition Business Plan: DLT Resolution Stock Symbol: DLTI
- Fyt-02 Launches on Kickstarter The Smart Sensor That Turns Any Chair Into a Posture & Movement Track
- YieldOMega Launches $DOUB Airdrop Campaign Ahead of TimeCurve Launch
- Kaltra Expands Microchannel Water Coil Line for U.S. HVAC Market With New Corrosion-Resistant Tube Technology
- Collectibles EvoRelic Celebrates Stellar 4.8-Star Customer Rating
- Phoenix Hip-hop Artist Rhymi Hits 23k Monthly Listeners 12 Days After Album Release
- Pediatrician Launches "Confessions of a Detective Doctor" Children's Book Series
- Integrated Maintenance Platforms Are Transforming Aircraft Operations
- T. Jones Group's Cameron Jones Serves as Judge for the 2026 CHBA National Awards for Housing Excellence
- Derek Advanced Tracking Systems Revolutionizes Asset Monitoring with Advanced Technology
- The AI Direction Deficit: TripleTen Study Finds Staff Get Told to Use AI — But Not Trained to Use It
- Spokane: Flags Lowered for Peace Officers Memorial Day
- $29.8 Million Record Setting Q1 with Boosted Annual Guidance to $160 Million for Expanding Pre-Owned Boat Dealer: Off The Hook YS, Inc. N Y S E: OTH
- All About Technology Celebrates 25 Years of Bridging Detroit's Digital Divide
- iatroX surpasses 500,000 clinical queries and expands specialist exam coverage
- Inside-Out Hollywood: The Relentless Rise of Joseph Nybyk (AKA Joseph Neibich)
- Lumetra Launches Engram, an MCP-Native Memory Layer Scoring 91.6% on LongMemEval
- Spokane Parks & Recreation's Therapeutic Recreation Receives Donation